# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Mahalia Jackson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML035-SYN
- Date: 2026-03-09
- Fictional facility: St. Posthumous Health Center
- Fictional author: Beatrice Fontenot, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Cardiac test results and the start of treatment. **S**

## History of present illness

Ms. Jackson returns two weeks after the consultation with the results of her heart and eye tests. The Holter recorded first-degree atrioventricular block throughout, ectopic beats making up 6 percent of all beats, and three short runs of ventricular tachycardia, one during her palpitations. The echocardiogram and cardiac MRI show a mildly reduced pumping function (ejection fraction 47 percent) with scarring in the base of the septum and the side wall, and the FDG-PET three days ago shows active inflammation at the same sites. The eye examination was normal. Hepatitis B and C tests were negative, and she is not immune to hepatitis B. Cultures from the EBUS samples show no growth at three weeks. She is breathless on one flight of stairs, has had two more spells of palpitations, and has not fainted. She saw Dr. Asante-Miller and the cardiology team this morning. She asked whether she will sing again and was told that, with treatment, most people return to their work. She has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| Holter | PR 230 to 250 ms; ventricular ectopy 6 percent; three runs of nonsustained ventricular tachycardia up to 8 beats |
| Echocardiogram and MRI | Ejection fraction 47 percent; patchy enhancement of the basal anteroseptum and inferolateral wall |
| FDG-PET | Focal myocardial uptake matching the MRI; active hilar and mediastinal nodes |
| Eyes | No uveitis; normal pressures |
| Infection screening | Hepatitis B and C negative; not immune to hepatitis B; cultures no growth at three weeks |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired; no fever or weight loss |
| Respiratory | Positive | Breathless on one flight of stairs; dry cough |
| Cardiovascular | Positive | Two more spells of palpitations; no fainting, chest pain or ankle swelling |
| Eyes | Negative | No redness or blurred vision |
| Endocrine | Negative | No thirst or frequent urination |
| Psychiatric | Positive | Frightened by the heart findings, steadied by her faith; PHQ-9 7; no thoughts of self-harm |

6 systems reviewed. **S**

## Current medications

- Prednisone 20 mg oral tablet, two tablets (40 mg) by mouth each morning **S**
- Methotrexate 2.5 mg oral tablet, six tablets (15 mg) by mouth once a week on Sundays **S**
- Folic acid 1 mg oral tablet, one tablet by mouth daily **S**
- Atovaquone 750 mg/5 mL oral suspension, 1500 mg (10 mL) by mouth once daily with food **S**
- Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/78 mmHg; pulse 80 bpm; respirations 18/min; temperature 36.6 °C; oxygen saturation 95% on room air; weight 91.2 kg; BMI 31.6 kg/m². All vital signs are synthetic.

Hemoglobin: 12.6 g/dL; White cell count: 4.8 10*3/uL; Lymphocyte count: 0.9 10*3/uL (low); Platelets: 240 10*3/uL; Creatinine: 1.02 mg/dL; eGFR (CKD-EPI 2021): 66 mL/min/1.73 m²; Glucose: 101 mg/dL (high); Calcium: 10.6 mg/dL (high); ALT: 27 U/L; AST: 29 U/L; Alkaline phosphatase: 124 U/L (high); Albumin: 4 g/dL; NT-proBNP: 240 pg/mL (high); PHQ-9: 7. All results are synthetic.

## Change since baseline

- Hemoglobin: 12.4 g/dL at baseline, 12.6 g/dL at this visit **S**
- White cell count: 4.6 10*3/uL at baseline, 4.8 10*3/uL at this visit **S**
- Lymphocyte count: 0.9 10*3/uL (low) at baseline, 0.9 10*3/uL (low) at this visit **S**
- Platelets: 232 10*3/uL at baseline, 240 10*3/uL at this visit **S**
- Creatinine: 1.08 mg/dL (high) at baseline, 1.02 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 62 mL/min/1.73 m² at baseline, 66 mL/min/1.73 m² at this visit **S**
- Glucose: 104 mg/dL (high) at baseline, 101 mg/dL (high) at this visit **S**
- Calcium: 10.8 mg/dL (high) at baseline, 10.6 mg/dL (high) at this visit **S**
- ALT: 28 U/L at baseline, 27 U/L at this visit **S**
- AST: 30 U/L at baseline, 29 U/L at this visit **S**
- Alkaline phosphatase: 128 U/L (high) at baseline, 124 U/L (high) at this visit **S**
- Albumin: 4 g/dL at baseline, 4 g/dL at this visit **S**
- NT-proBNP: 210 pg/mL (high) at baseline, 240 pg/mL (high) at this visit **S**

## Immunizations given today

- Pneumococcal conjugate vaccine (PCV20), before immunosuppression **S**
- Recombinant zoster vaccine, dose 1 of 2 **S**
- Hepatitis B vaccine (adjuvanted, two-dose series), dose 1 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 91.2 kg; blood pressure 124/78, pulse 80 with occasional ectopic beats |
| Respiratory | Clear to auscultation |
| Cardiovascular | Occasional ectopic beats; no murmur, gallop or ankle swelling; jugular venous pressure normal |
| Mouth | No thrush; teeth in good repair |
| Skin | No rash or plaques |
| Psychiatric | Thoughtful; asks about her voice and travel |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Cardiac sarcoidosis** (D86.85). Cardiac sarcoidosis by the HRS criteria: sarcoidosis proven in lymph nodes, with unexplained first-degree atrioventricular block, nonsustained ventricular tachycardia, scar on MRI, matching active inflammation on PET and an ejection fraction of 47 percent. Active cardiac inflammation is treated with glucocorticoids and a steroid-sparing agent. The ejection fraction is above 35 percent, but the scar and nonsustained ventricular tachycardia make an electrophysiology study the next step to decide whether she needs a defibrillator. Dr. Asante-Miller and cardiology agree. **S**
   - Prednisone 40 mg each morning, with a taper planned over about six months.
   - Methotrexate 15 mg once weekly with folic acid 1 mg daily, increasing to 20 mg if tolerated.
   - Metoprolol succinate 25 mg daily.
   - Electrophysiology study next week, with a dual-chamber defibrillator if sustained ventricular tachycardia is induced.
   - Repeat FDG-PET after about five months of treatment.
2. **Pulmonary sarcoidosis with lymph node involvement** (D86.2). The same treatment covers the lungs, where function is impaired and she has symptoms. **S**
   - Repeat lung function in about two months.
3. **Long-term systemic glucocorticoid treatment** (Z79.52). She will take prednisone for many months, with prediabetes (A1c 5.9%) and high calcium. Bone protection without calcium tablets while calcium is high; pneumocystis prophylaxis while prednisone is 20 mg or more with methotrexate, using atovaquone because trimethoprim-sulfamethoxazole adds to methotrexate's effect on the marrow; vaccines today, before immunosuppression takes hold. **S**
   - Bone density scan next week, then alendronate 70 mg weekly.
   - Atovaquone 1500 mg daily.
   - PCV20, the first recombinant zoster dose and the first hepatitis B dose today.
   - Home glucose checks twice a week; no alcohol on methotrexate.
4. **Hypercalcemia** (E83.52). Calcium 10.6 mg/dL; expected to fall on prednisone. **S**
   - Calcium at the next visit.
5. **Palpitations with conduction disease** (R00.2). Explained by cardiac sarcoidosis, diagnosed today; superseded. **S**
   - Problem resolved.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Holter monitoring | When the ECG is abnormal or there are palpitations | Up to date | Ventricular ectopy 6 percent; three runs of nonsustained ventricular tachycardia; first-degree block; no high-grade block |
| Imaging | Echocardiogram and cardiac MRI | When cardiac involvement is suspected | Up to date | Ejection fraction 47 percent; late gadolinium enhancement about 9 percent of left ventricular mass |
| Imaging | Cardiac FDG-PET | Before glucocorticoids, then three to six months into treatment | Up to date | Three days ago: active myocardial inflammation matching the MRI; repeat after about five months |
| Examination | Eye examination | At diagnosis, then yearly | Up to date | Five days ago: normal |
| Laboratory | Exclusion of other granulomatous causes | At diagnosis | Ordered | Cultures no growth at three weeks; final at six to eight weeks |
| Laboratory | Methotrexate safety: blood count, liver tests and creatinine | Before starting; every two to four weeks for the first three months; then every eight to twelve weeks | Completed today | Baseline: hemoglobin 12.6 g/dL, white cells 4.8, lymphocytes 0.9, platelets 240; ALT 27, AST 29, alkaline phosphatase 124 U/L, albumin 4.0 g/dL; creatinine 1.02 mg/dL, eGFR 66 |
| Laboratory | Hepatitis B and C screening | Before immunosuppressive treatment | Up to date | Negative; not immune to hepatitis B, so vaccination starts today |
| Laboratory | Serum calcium | At diagnosis, then at each treatment visit while it was raised or vitamin D is given | Completed today | 10.6 mg/dL |
| Laboratory | Glucose before glucocorticoids | At the start, then at each visit | Completed today | Glucose 101 mg/dL; A1c 5.9% at the first visit |
| Laboratory | NT-proBNP | At the cardiac diagnosis and when symptoms change | Completed today | 240 pg/mL |
| Imaging | Bone density (DXA) and FRAX | At the start of glucocorticoids expected to last three months or more | Ordered | Booked for next week |
| Medication safety | Pneumocystis prophylaxis | While prednisone is 20 mg or more with a second immunosuppressant | Completed today | Atovaquone started; trimethoprim-sulfamethoxazole avoided with methotrexate |
| Medication safety | Vaccination before immunosuppression | Before or as treatment starts | Completed today | PCV20, recombinant zoster dose 1 and hepatitis B dose 1 given today; influenza at the first visit; no live vaccines |
| Referral | Cardiology and electrophysiology | When cardiac sarcoidosis is diagnosed | Referred | Seen with Dr. Asante-Miller today; electrophysiology study booked for next week |
| Survey | Depression screen (PHQ-9) | At diagnosis and at each phase of treatment | Completed today | PHQ-9 7 |

## Goal progress

- Tissue diagnosis with other causes excluded, and screening of the eyes, heart, calcium, liver and kidneys, within four weeks of presentation. Outcome by 2026-03-09: EBUS in nine days; eye examination, Holter, echocardiogram, cardiac MRI and FDG-PET within four weeks. **S**
- Calcium in the normal range within three months. In progress; target 2026-05-11. **S**
- FVC and DLCO improved by at least 10 percent of predicted within six months. In progress; target 2026-08-24. **S**
- No myocardial FDG uptake on repeat PET after about six months of treatment, with left ventricular function stable or better. In progress; target 2026-08-24. **S**
- Prednisone at 10 mg a day or less by six months, with methotrexate as the steroid-sparing agent. In progress; target 2026-08-24. **S**
- Back on stage with a schedule she can sustain, with her voice protected. In progress; target 2026-08-24. **S**

## Medication changes

- Started: Prednisone 20 mg oral tablet, two tablets (40 mg) by mouth each morning **S**
- Started: Methotrexate 2.5 mg oral tablet, six tablets (15 mg) by mouth once a week on Sundays **S**
- Started: Folic acid 1 mg oral tablet, one tablet by mouth daily **S**
- Started: Atovaquone 750 mg/5 mL oral suspension, 1500 mg (10 mL) by mouth once daily with food **S**
- Started: Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily **S**

## Guideline basis

- Crouser ED, et al. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020;201(8):e26-e51 (PMID 32293205) (2020), American Thoracic Society
- Baughman RP, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J 2021;58(6):2004079 (PMID 34140301) (2021), European Respiratory Society
- Birnie DH, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11(7):1305-1323 (PMID 24819193) (2014), Heart Rhythm Society
- Cheng RK, et al. Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association. Circulation 2024;149(21):e1197-e1216 (PMID 38634276) (2024), American Heart Association
- Humphrey MB, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 2023;75(12):2088-2102 (PMID 37845798) (2022), American College of Rheumatology
- Singh JA, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64(5):625-639 (PMID 22473917) (methotrexate laboratory monitoring) (2012), American College of Rheumatology
- Adult Immunization Schedule by Medical Condition and Other Indication (2026), Centers for Disease Control and Prevention
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Bone density next week; electrophysiology study next week. No driving for a week after any device implant. Nine-week review with lung function and blood tests. Call 911 for fainting, a sustained racing heart or a defibrillator shock. **S**
- Next scheduled visit 2026-05-11: nine weeks of treatment: lung function, calcium, methotrexate safety, the new defibrillator, steroid effects, and her concert schedule. **S**
